Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, placebo-controlled, two parallel groups, international multicenter trial to evaluate the effect of Plerixafor in acute respiratory failure related to COVID-19 (LEONARDO)

Next Previous
Search
Trial Profile

A randomized, double-blind, placebo-controlled, two parallel groups, international multicenter trial to evaluate the effect of Plerixafor in acute respiratory failure related to COVID-19 (LEONARDO)

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 03 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Plerixafor (Primary)
  • Indications Adult respiratory distress syndrome
  • Focus Therapeutic Use
  • Acronyms LEONARDO
  • Sponsors 4Living Biotech

    • Most Recent Events

    • 25 Sep 2023 This trial has been discontinued in Spain.
    • 07 Apr 2023 Status changed from active, no longer recruiting to withdrawn prior to enrolment.
    • 22 Dec 2022 This trial has been discontinued in Netherlands (Global end date 01/10/2022), according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top